ReviewReproduction (Cambridge, England)2025
PAPPA's role in female reproduction.
Review in Reproduction (Cambridge, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- XGBoost-based analysis of maternal and biochemical factors associated with spontaneous preterm birth: a retrospective cohort study.BMC pregnancy and childbirth · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
In brief: This review represents a multispecies summary of the role of pappalysins in female reproductive health. It discusses the potential use of PAPPA and PAPPA2 as biomarkers for oocyte and embryo quality and fetal development. Abstract: Pappalysin 1 and 2 (PAPPA and PAPPA2) are metzincin metalloproteinases expressed in the ovaries, endometrium, placenta, and several other organs. These enzymes are responsible for the liberation and regulation of localized bioactive insulin-like growth factors 1 and 2 (IGF1 and IGF2) via the proteolytic cleavage of insulin-like growth factor binding proteins. Several studies have implicated pappalysins as vital components for female fecundity. During the reproductive cycle, PAPPA peaks in dominant ovarian follicles before ovulation due to its response to gonadotropins, increasing follicular IGF availability. In human in vitro fertilization studies, PAPPA has been tested as a biomarker of oocyte and embryo quality. Studies with null mice resulting in offspring with reduced body weight and bone density have demonstrated the requirement of PAPPA for normal fetal development. Evidence supports a role for PAPPA in the establishment and maintenance of viable pregnancies through its influence on endometrial receptivity. Under the influence of PAPPA within the placenta, IGF1 and IGF2 influence mitogenic activity, trophoblastic invasion, and placental development. In addition, PAPPA has been proposed as a biomarker to identify aneuploidies in utero as well as a biomarker to recognize ectopic pregnancies. This narrative review examines PAPPA and PAPPA2 expression and localization, regulation, and function in the female reproductive tract in multiple species. Furthermore, it examines the role of PAPPA and PAPPA2 preceding and throughout pregnancy and as a molecular marker of oocyte maturation, embryo quality and development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.